Post by
subaru1i on Mar 29, 2024 10:29am
LABS has a 'weak spot' but is a wonderful 'blue print'
Although LABS can now tout global customers, U.S., Germany, Australia, Brazil, etc they do not have true 'global capacity' especially for anti-microbial and anti-viral capacity on a global scale but they do provide a wonderful 'blue print' which can easily be replicated in a much larger capacity facility.
Forward planning would indicate that Pfizer has already made plans to break ground on a much larger extraction facility in the U.S. once the DEA reschedules cannabinoids.
Mr. Pidduck, would that incorporate the definition of JOINT VENTURE that is especially 'accretive'.
I know I'm a bit ahead of the curve here on this board Mr. Pidduck so don't let my words rattle you.